Eledon Pharmaceuticals Q2 net loss widens on warrant liability changes

Eledon Pharmaceuticals

13/08/2026 21:16

Overview
US biotech reported Q2 net loss widened yr/yr, driven by non-cash warrant liability changes
Operating expenses for Q2 fell compared to the prior-year period
Company expects cash and investments to fund operations into Q2 2027

Outlook
Company expects current cash to fund operations into Q2 2027

Result Drivers
OPERATING EXPENSES - Q2 operating expenses declined yr/yr, mainly due to lower research and development spending

Company press release: ID:nGNX4PhWKL

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Loss
 
$31.63 mln
 
Q2 Income from Operations
 
-$22.87 mln
 
Q2 Operating Expenses
 
$22.87 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Eledon Pharmaceuticals Inc is $8.00, about 112.2% above its August 12 closing price of $3.77

Reuters Recommended Reads
Aug 11 - Achieve Life Sciences Q2 loss widens on warrant liabilities
Aug 12 - Unicycive Therapeutics Q2 net loss narrows on warrant liability change
Aug 10 - Cell therapy developer ProKidney's Q2 operating loss widens as trial costs rise

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)